Is withdrawal of nocturnal hyperhydration possible in children with primary hyperoxaluria treated with RNAi?
Author:
Publisher
Springer Science and Business Media LLC
Subject
Nephrology
Link
https://link.springer.com/content/pdf/10.1007/s40620-023-01611-1.pdf
Reference15 articles.
1. Méaux MN, Sellier-Leclerc AL, Acquaviva-Bourdain C, Harambat J, Allard L, Bacchetta J (2022) The effect of lumasiran therapy for primary hyperoxaluria type 1 in small infants. Pediatr Nephrol 37(4):907–911. https://doi.org/10.1007/s00467-021-05393-1
2. Cochat P, Rumsby G (2013) Primary hyperoxaluria. N Engl J Med 369(7):649–658. https://doi.org/10.1056/NEJMra1301564
3. Cochat P, Hulton SA, Acquaviva C, Danpure CJ, Daudon M, De Marchi M et al (2012) Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment. Nephrol Dial Transpl 27(5):1729–1736. https://doi.org/10.1093/ndt/gfs078
4. Sas DJ, Magen D, Hayes W, Shasha-Lavsky H, Michael M, Schulte I et al (2022) Phase 3 trial of lumasiran for primary hyperoxaluria type 1: a new RNAi therapeutic in infants and young children. Genet Med 24(3):654–662. https://doi.org/10.1016/j.gim.2021.10.024
5. Garrelfs SF, Frishberg Y, Hulton SA, Koren MJ, O’Riordan WD, Cochat P et al (2021) Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1. N Engl J Med 384(13):1216–1226. https://doi.org/10.1056/NEJMoa2021712
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1: Results from a Phase III Clinical Trial;Kidney International Reports;2024-07
2. Primäre Hyperoxalurie;Nephrologie aktuell;2024-07
3. Diagnosis and management of primary hyperoxalurias: best practices;Pediatric Nephrology;2024-05-16
4. Navigating the Evolving Landscape of Primary Hyperoxaluria: Traditional Management Defied by the Rise of Novel Molecular Drugs;Biomolecules;2024-04-23
5. Lumasiran: A Review in Primary Hyperoxaluria Type 1;Drugs;2024-01-22
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3